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Abstract According to international recommendations, the se-
lection of the biologic disease modifying anti-rheumatic drug
(bDMARD) for rheumatoid arthritis (RA) is mainly left to the
clinician’s preference. We analyzed the real-life factors influenc-
ing the first-line choice or the switching strategy, focusing on the
prescription of abatacept (ABA) or tocilizumab (TCZ) compared
to TNFα inhibitors (TNFi). Patients enrolled in the Lombardy
Rheumatology Network (LORHEN) Registry after January 1,
2010, when all considered bDMARD agents were available,
were included. The population was divided into Bfirst-^ and
Bsecond-line^ bDMARD. We included 1910 patients (first line
n = 1264, second line n = 646). Age was higher in ABA or TCZ
vs TNFi treated patients (p < 0.0001). Positive latent tuberculosis
screening was associated with first-line ABA (p = 0.002).
Methotrexate (MTX) combination therapy was lower in the
TCZ group (p = 0.02). The type (dyslipidemia, hypertension,
pulmonary disease) and the number of comorbidities influenced
the choice towards ABA (p = 0.01). Multinomial logistic regres-
sion demonstrated that a second-line treatment, higher age, dys-
lipidemia, pulmonary disease, other comorbidities, and extra-
articular RA manifestations were associated with ABA com-
pared to TNFi. TCZwas associated with a second-line treatment,
higher age, and more severe disease activity. Stopping the first
bDMARD due to adverse events (AE) influenced the choice
towardsABA. In real life, higher age and comorbidities influence
the choice towards ABA and TCZ compared to TNFi. ABAwas
preferred in case of suspension of previous treatments due to AE.
After failing a first-line TNFi, swapping to a differentmechanism
of action is more common.
Keywords Abatacept . Biologic therapy . Rheumatoid
arthritis . TNF inhibitors . Tocilizumab . Treatment choice
Introduction
In the last decade, major advances have been brought to the
management of rheumatoid arthritis (RA). Biologic diseasemod-
ifying anti-rheumatic drugs (bDMARDs) have become the stan-
dard of care for the treatment of RA not adequately responding to
conventional synthetic DMARDs (csDMARDs). To date, sever-
al bDMARDs acting at different levels of the immune response
have been licensed for the treatment of RA. TNFα inhibitors
(TNFis) encompass five different agents: infliximab (IFX), in-
cluding the recently approved infliximab bio-similar (bs-IFX);
etanercept (ETA), adalimumab (ADA); golimumab (GOL); and
certolizumab pegol (CZP) [1], allowing to choose among differ-
ent routes and frequency of administration and peculiar
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pharmacokinetic characteristics. The introduction of the
interleukin-6 (IL-6) receptor blocking monoclonal antibody toci-
lizumab (TCZ), the T-cell co-stimulation inhibitor abatacept
(ABA), and the anti-CD20 B-cell depleting agent rituximab
(RTX) have further increased the therapeutic armamentarium to
treat RA.
However, despite the wide range and evolving spectrum of
bDMARD options available, little is still known on the best
approach to the individual patient, and the choice of the first
line or sequencing bDMARDs is still largely left to the clini-
cian’s choice and personal experience.
Indeed, randomized controlled trials (RCTs), indirect com-
parison studies, meta-analysis, and head to head studies have
failed to demonstrate a significant difference among the dif-
ferent classes of bDMARDs in terms of efficacy on clinical,
functional, and radiographic outcomes [2–5]. The only excep-
tion being probably represented by TCZ monotherapy [6].
International recommendations [7] do not provide a prefer-
ence on the mechanism of action (MoA) to be chosen as first
bDMARD therapy. TNFis, ABA or TCZ, and, under certain
circumstances such as history of lymphoma or demyelinating
disease, RTX are recommended as first-line biologic agents.
Switching among bDMARDs is also mainly left to the clini-
cian’s decision between a second TNFi or a different MoA [6,
7]. However, it is generally accepted that switching from a
second to a third TNFi is associated with significantly lower
response to treatment and a different MoA should be consid-
ered in these patients [8]. Only scant and cautious acknowl-
edgement of potential differences in the safety profile of avail-
able bDMARDs comes from the 2015 American College of
Rheumatology (ACR) guideline for the treatment of RA [9]
that indicates ABA, noteworthy with a very low level of evi-
dence, as the drug of choice in case of previous serious infec-
tions and ABA or TCZ over TNFis in patients with a previous
lymphoproliferative disorder.
Nevertheless, real-life data have emphasized prescription dif-
ferences among bDMARDs, possibly influenced by the emerg-
ing evidence demonstrating a better safety profile of ABA [10,
11], and the unique efficacy of TCZ used as monotherapy, com-
pared to TNFis. Moreover, in clinical practice, several other fac-
tors may be advocated as drivers of the choice of a specific agent
such as comorbidities, host-related risk factors for infections,
cardiovascular risk, the patient’s compliance and preference for
a specific route of administration, predictive biomarkers such as
seropositivity for rheumatoid factor (RF) and/or anti-citrullinated
protein antibodies (ACPA), and, eventually, also cost-
effectiveness [12]. These factors are not always adequately sup-
ported by evidence-based medicine (EBM) but are perceived as
very relevant by experts in the field and supported by science-
based medicine (SBM).
The aim of this study was to retrospectively analyze the
factors influencing the choice of the first-line bDMARD or
the switching strategy in a large cohort of real-life RA patients
enrolled in the Italian Lombardy Rheumatology Network
(LORHEN) Registry, focusing on the prescription of ABA
or TCZ compared to TNFis.
Materials and methods
Patients enrolled in the Lombardy Rheumatology Network
(LORHEN) Registry [13] including patients treated with
bDMARDs in eight rheumatologic centers inNorthern Italywere
analyzed. The analysis was limited to patients enrolled after
January 1, 2010, when all three different MoA were available.
All patients provided written informed consent. The study pop-
ulation was divided into Bfirst-line^ and Bsecond-line^
bDMARD. Comorbidities were categorized into organ systems
groups (pulmonary disease, cardiovascular disease, arterial hy-
pertension, dyslipidemia, diabetes mellitus, peripheral neuropa-
thy, osteoporosis, thyroid autoimmune disease, other comorbid-
ities not belonging to the previous categories).
Statistical analysis
Analysis was performed using Stata 14.1 (StataCorp, College
Station, TX, USA). A two-sided p value was considered statisti-
cally significant. Continuous data were described as mean and
standard deviation (SD) or median and quartiles (IQR) and com-
pared with the one-way ANOVA or the Kruskall-Wallis test.
Categorical data were summarized as counts and percent and
compared with the Fisher exact test. For pairwise post hoc com-
parison ofABA andTCZvs TNFis, significancewas set at 0.025
(Bonferroni correction). Multinomial logistic regression was
used to assess the probability of using either treatments given
line of treatment and adjusted for baseline characteristics and
comorbidities. Confounders with p < 0.05 at univariate analysis
together with extra-articular manifestations (of clinical interest)
were included in the model in addition to line. The relative risk
ratios (RRR) of choosing ABA rather than TNFi, or TCZ rather
than TNFi, were reported together with 95% confidence inter-
vals. Identification of predictors of the choice of treatment was
also performed in a separate pre-specified subgroup analysis by
line of treatment. Forrest plots were used to display results.
Results
First-line bDMARD treatment
A total of 1910 patients were included. Patients treated with a
first-line bDMARD were 1264 (ABA first line: 115 patients;
TCZ first line: 130; TNFi first line: 1019). Second-line
bDMARD treatment included 646 patients (ABA second line:
143; TCZ second line: 97; TNFi second line: 406). General
characteristics of the study population are displayed in
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Table 1. Mean age at the time of first bDMARD initiation was
statistically different for ABA vs TNFi (58.74 ± 13.39 vs
53.42 ± 13.66; p = 0.0003) and for TCZ vs TNFi
(57.84 ± 10.89 vs 53.42 ± 13.66; p = 0.002).
ABA was associated with a higher prevalence of positive
LTBI status (29.63%) compared to TCZ (16.26%); p = 0.04,
and TNFi (15.64%); p = 0.003. There were no significant
differences among the three groups regarding the pre-
treatment screening for HBVor HCV infections.
Data regarding treatment preceding the initiation of the
first-line bDMARD and the current therapeutic characteristics
are presented in Table 2. TCZ was significantly more pre-
scribed as monotherapy compared to ABA (p = 0.02) and
TNFi (p = 0.01).
Comorbidities and first-line bDMARD
The prevalence of comorbidities according to the organ sys-
tem involved is shown in Table 3 Dyslipidemia was recorded
in 14.78% of patients treated with ABA, whereas 10%
(p = 0.99) of those treated with TCZ and 7.16% (p = 0.03)
of patients started on TNFi were dyslipidemic. The compari-
son between TCZ and TNFi was not significant (p = 0.86).
Arterial hypertension was more represented in ABA group
compared to TNFi (p = 0.003).
Pulmonary comorbidities were statistically more represent-
ed in the ABA group compared to the TNFi group
(p < 0.0001) and, not reaching statistical significance, the
TCZ group (p = 0.07). The comparative frequency of pulmo-
nary comorbidities between TCZ and TNFi was also per-
formed (p = 0.57).
The prevalence of comorbidities categorized as Bother^ in
the LORHEN Registry were reported to affect 67.83% of
patients in the ABA group, 47.69% in the TCZ group
(p = 0.006), and 41.51% of the TNFi group (p = <0.0001).
Pulmonary extra-articular involvement of disease was
reported in 4 (3.48%) patients in the ABA treated
group, 4 (3.08%) of the TCZ group, and 18 (1.77%)
of the TNFi group; p = 0.25. Rheumatoid vasculitis
was recorded in only 1 patient in the TNFi group.
Rheumatoid nodules were reported for 6 (5.22%) pa-
tients treated with first-line ABA, 1 (0.77%) in the
TCZ group, and 25 (2.45%) in the TNFi group;
p = 0.09. Ocular involvement was reported in 6
(0.59%) patients treated with TNFi and none of the
patients in the two other therapeutic groups (p = 1.0)
Having ≥two comorbidities was significantly associated
with the prescription of ABA compared to both TCZ
(p = 0.01) and TNFi (p = 0.02); Fig. 1.
Second-line bDMARD treatment
The general characteristics of the study population at the time
of treatment switch to a second-line bDMARD are shown in
Table 1.
Table 1 General characteristics of the study population at first and second-line bDMARD
ABA first line N = 115 TCZ first line N = 130 TNFi first line N = 1019 p
Sex (M/F) 94/21 110/20 798/221 0.21
Age at bDMARD initiation
(mean ± SD)
58.74 ± 13.39 57.84 ± 10.89 53.42 ± 13.66 <0.0001
Disease duration
(months; median; IQR)
66.35 (26.38; 156.74) 70.95 (30.39; 146.45) 64.33 (26.55; 138.19) 0.76
ACPA positivea (N/%) 51 (75%) 45 (73.77%) 385 (72.50%) 0.93
RF positivea (N/%) 55 (67.07%) 41 (64.06%) 412 (66.03%) 0.92
DAS28 (mean ± SD) 5.12 ± 1.29 5.21 ± 1.28 5.02 ± 1.28 0.26
HAQ (mean ± SD) 1.27 ± 0.65 1.19 ± 0.66 1.20 ± 0.01 0.61
Current cigarette
smoking statusa (N/%)
21 (24.42%) 21 (20.19%) 159 (21.63%) 0.29
ABA second line N = 143 TCZ second line N = 97 TNFi second line N = 406 p
Sex (M/F) 120/23 74/23 351/55 0.05
Age at second-line bDMARD
initiation (mean ± SD)
58.80 ± 12.99 55.55 ± 4.93 54.62 ± 13.83 0.008
Disease duration
(months; median; IQR)
88.42 (49.34;192.53) 98.68 (45.53; 213.82) 98.36 (56.12;182.80) 0.92
DAS28 (mean ± SD) 4.88 ± 1.27 5.20 ± 1.14 4.57 ± 1.41 <0.0001
HAQ (mean ± SD) 1.22 ± 0.69 1.22 ± 0.71 1.05 ± 0.66 0.02
HAQ Health Assessment Questionnaire, ACPA anti-citrullinated protein antibodies, RF rheumatoid factor
a Data not available for the whole population; significant p-values in italics
Clin Rheumatol (2017) 36:753–761 755
The interruption of the first-line bDMARD due to adverse
events (AE) influenced the choice of the second-line treatment
in favor of ABA compared to TNFi: relative risk ratio (RRR):
3.37 (CI 1.28–8.83), Fig. 3, panel b. Neither ABA nor TCZ
choice as second-line drugs was influenced by the discontin-
uation of the previous bDMARD due to primary or secondary
inefficacy.
Age was significantly higher in the ABA second-line group
compared to TNFi (p = 0.008) but not compared to TCZ
(p = 0.20). Age difference between TCZ and TNFi was not
significant (p = 0.84).
Disease activity at the time of switch was significantly
higher when comparing ABA vs TNFi (p = 0.03) and TCZ
vs TNFi (p < 0.0001). The difference in DAS28 between
Table 2 Treatment characteristics of the study population
ABA first line N = 115 TCZ first line N = 130 TNFi first line N = 1019 p
Number of previous csDMARDS
(median; IQR)
2 (1; 3) 2 (1; 3) 2 (1; 3) 0.56
Previous glucocorticoid (N/%) 110 (96.49%) 126 (97.67%) 943 (96.32%) 0.84
Time since first-line bDMARD
initiation (months; median; IQR)
11.74 (4.14;22.53) 12.06 (2.14;24.24) 12.34 (3.82; 30.39) 0.16
Concomitant MTX (N/%) 79 (68.70%) 66 (50.11%) 655 (64.28%) 0.006
Concomitant other csDMARDsa 48 (41.74%) 63 (48.46%) 477 (46.81%) 0.53
Concomitant glucocorticoid (N/%) 96 (83.48%) 101 (77.69%) 772 (75.76%) 0.17
bDMARD suspension (N/%) 34 (29.57%) 36 (27.69%) 429 (42.10%) <0.0001
ABA second line N = 143 TCZ second line N = 97 TNFi second line N = 406
Concomitant glucocorticoid (N/%) 122 (85.31%) 83 (85.57%) 341 (83.99%) 0.91
Concomitant MTX (N/%) 92 (64.34%) 53 (54.64%) 276 (67.98%) 0.04
Concomitant other csDMARDs 73 (51.05%) 49 (50.52%) 220 (54.19%) 0.70
csDMARDs: conventional synthetic DMARDs; MTX: methotrexate
a Other csDMARDs different fromMTX;might be prescribed in combinationwithMTX (i.e., sulphasalazine, leflunomide); significant p-values in italics
Table 3 Prevalence of










Pulmonary disease 19 (16.52%) 9 (6.92%) 59 (5.79%) <0.0001
Cardiovascular 11 (9.57%) 6 (4.62%) 63 (6.18%) 0.25
Arterial hypertension 45 (39.13%) 40 (30.77%) 249 (24.44%) 0.002
Dyslipidemia 17 (14.78%) 13 (10%) 73 (7.16%) 0.02
Diabetes mellitus 8 (6.96%) 9 (6.92%) 49 (4.81%) 0.33
Peripheral neuropathy 2 (1.74%) 1 (0.77%) 7 (0.69%) 0.29
Osteoporosis 15 (13.04%) 14 (10.77%) 125 (12.27%) 0.86
Thyroid autoimmune
disease
17 (14.78%) 13 (10%) 109 (10.7%) 0.39








Pulmonary disease 12 (8.39%) 10 (10.31%) 30 (7.39%) 0.57
Cardiovascular 16 (11.19%) 4 (4.12%) 27 (6.65%) 0.09
Arterial hypertension 55 (38.46%) 34 (35.05%) 126 (31.03%) 0.25
Dyslipidemia 20 (13.99%) 7 (7.22%) 33 (8.13%) 0.10
Diabetes mellitus 10 (6.99%) 2 (2.06%) 25 (6.16%) 0.21
Peripheral neuropathy 5 (3.50%) 1 (1–03%) 1 (0.25%) 0.006
Osteoporosis 24 (16.78%) 14 (14.43%) 63 (15.52%) 0.89
Thyroid autoimmune
disease
22 (15.38%) 16 (16.49%) 53 (13.05%) 0.56
Other comorbidities 78 (54.55%) 45 (46.34%) 191 (47.04%) 0.27
Significant p-values in italics
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ABA and TCZ was not significant. Combination therapy with
MTXwith a second-line bDMARDwas prescribed in 54.64%
of patients treated with TCZ compared to 67.98% of patients
in the TNFi group (p = 0.02) and 64.34% of patients on ABA
(p = 0.08). The difference of concomitant MTX rates between
ABA and TNFi was not significant (p = 0.47).
Comorbidities and second-line bDMARD
The prevalence of comorbidities at the time of switch to a
second-line bDMARD is presented in Table 3. Peripheral
neuropathy was significantly less represented in the TNFi
group compared to ABA (p = 0.006).
Extra-articular manifestations of disease were not signifi-
cantly more represented in any therapeutic group in the
second-line bDMARD population.
Multinomial logistic regression analysis, exploring the role
of treatment line adjusted for comorbidities and baseline char-
acteristics on the choice of bDMARD, revealed that the choice
of ABA compared to TNFi was significantly influenced by a
second-line of treatment, age, extra-articular vasculitic mani-
festations of disease, dyslipidemia, pulmonary comorbidities,
neuropathies, and other comorbidities in general. When ana-
lyzing the drivers of choice for TCZ, compared to TNFi, the
following factors resulted significant: second line of treat-
ment, age, and DAS28 disease activity.
The relative risk of choosing ABA compared to TCZ on a
second-line bDMARD treatment was not significant.
The subanalysis of the factors influencing the choice of the
bDMARD according to the different lines of treatment re-
vealed that the choice of first-line ABA was influenced by
age, a positive LTBI screening, extra-articular ocular and vas-
culitic involvement, arterial hypertension, pulmonary comor-
bidities, and other comorbidities in general. First-line TCZ
choice was influenced by: age, extra-articular ocular and vas-
culitic involvement, diabetes, and neuropathies.
Regarding second-line treatment, ABA second-line was
mainly selected according to the following drivers: age, sus-
pension of first-line bDMARD due to AE, extra-articular
nodulosis, and neuropathy. On the other hand, high DAS28
Fig. 1 Prevalence of comorbidities in the study population. Difference
among the treatment groups of having ≥2 comorbidity compared to not
having comorbidities
Fig. 2 Multinomial logistic
regression analyzing the factors
associated with the choice of a
specific bDMARD (ABA or
TCZ) compared to TNFi
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disease activity, positive LTB screening, pulmonary or cardio-
vascular comorbidities, and neuropathy influenced the choice
of second-line TCZ vs TNFi. The Forrest plots describing the
drivers of choice of ABA and TCZ vs TNFi are represented in
Figs. 2 and 3.
Discussion
The introduction of bDMARDs to the standard of care for RA
has revolutionized the course of the disease. Despite the con-
stantly developing therapeutic options and an increasing shift
of interest towards the management of withdrawing
bDMARDs when remission is achieved [14–16], robust evi-
dence is still needed on the appropriate prescription strategy of
first-line bDMARD and switching strategy in real-life set-
tings. To the best of our knowledge, this is the first study
demonstrating that higher age and comorbidities influence
the choice towards ABA and TCZ compared to TNFi in a
large registry study. The interruption of previous bDMARD
treatments due to AE also drove the choice towards ABA.
Moreover, despite lack of a definite recommended strategy
coming from international guidelines, a tendency of swapping
to a different MoA after failing a first bDMARD seemed to be
the preferred approach in real life.
The management of elderly patients with RA is deemed to
increase in the future. Previous studies have shown that in-
creasing age is associated with reduced chances of receiving
TNFi compared to younger patients, despite higher disease
activity levels [17, 18]. Moreover, age and comorbidities have
been associated with a decreased response to ETA treatment
[19, 20]. A recent study analyzing the comparative effects of
bDMARDs on cardiovascular risk among more than 47,000
older patients with RA reported a higher risk of acute myo-
cardial infarction with TNFi (particularly ETA and IFX) com-
pared to ABA or TCZ [21]. Nevertheless, the influence of
comorbidities on disease activity and potentially on treatment
choices is not confined to older patients with RA [22]. In the
first study reporting the influence of comorbidities on disease
course in RA, about 27% of patients with early RA had al-
ready at least one chronic coexisting disease, the most fre-
quently reported being cardiovascular (29%), respiratory
(18%), and dermatological (11%) conditions [23].
In 2016, Innala et al. [24] reported an even higher preva-
lence of comorbidities, as high as 53.2%, in early RA patients.
The commonest being hypertension (27.3%), obstructive pul-
monary disease (13.9%), diabetes (8.0%), hypothyroidism
(6.3%), and malignancy (5.0%). Interestingly, after 5 years,
up to 41% of patients developed at least one new comorbidity,
mainly cardiovascular, neoplastic, or osteoporosis. The high
prevalence of comorbid conditions in patients with RA has
been confirmed by a number of studies, among which, the
COMOrbidities in Rheumatoid Arthritis (COMORA) study
[25], a large international, cross-sectional study recruiting
4586 patients, highlighted the high prevalence of comorbidi-
ties and related risk factors in patients with RA and the need
for an optimization of treatment.
The prevalence of comorbidities in our study was generally
in line with previous epidemiologic reports [25]; however, we
demonstrated that the number and the type of comorbidity
Fig. 3 Multinomial logistic regression analyzing the factors associated with the choice of a specific first-line (a) or second-line (b) bDMARD (ABA or
TCZ) compared to TNFi
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differ among the three different therapeutic agents and may
influence the choice of bDMARD treatment. First-line biolog-
ic agent was preferably ABAvs TCZ or TNFi in patients with
concomitant comorbidities such as dyslipidemia or hyperten-
sion. The presence of a concomitant pulmonary condition was
associatedwith a relative risk (RR) of 2.19 (95%CI: 1.05–2.4)
of choosing ABA compared to TNFi. Unfortunately, the na-
ture of this registry study does not allow to explore this finding
in deeper detail, but it may be speculated that interstitial lung
disease (ILD) might represent the main underlying pulmonary
comorbidities leading to the choice of ABA over TNFi [26,
27]. Another possible explanation could regard the infectious
risk. Our study demonstrated that in real life, ABA represents
the drug of choice in case of underlying infectious risk, such
as pre-treatment LTBI positive screening. A recent Italian
multidisciplinary expert panel named Tailored BIOlogic ther-
apy (ITABIO), aiming at defining an evidence-based decision-
al statements for the first-line-tailored biologic therapy in pa-
tients with rheumatic diseases, also concluded that LTBI pos-
itivity should drive the choice towards ABA, TCZ, or ETA
[12]. Knowing the pathophysiologic role of TNF in control-
ling and confining mycobacteria infections [28], the choice of
a different MoAwhenever possible might not seem unexpect-
ed. However, safety data regarding ABA demonstrated that
this agent is particularly associated with a lower incidence of
serious infections (SI), in general, compared to other
bDMARDs [10, 29]. The AMPLE trial [2], a head to head
comparison of ABA vs ADA demonstrated that overall AE
and serious infections were significantly lower with ABA: SI
rate of 3.8 compared to 5.8% in the ADA-treated group. Also,
the ATTEST trial reported considerably lower rates of SI in
patients treated with ABA (1.9%) vs IFX (8.5%) [30]. Ameta-
analysis by Salliot et al. confirmed that ABA did not signifi-
cantly increase the risk of SI in RA patients [31]. Our study
confirmed the real-life strategy of preferring ABA in case of
interruption of previous bDMARDs due to AE.
The significantly higher prevalence of monotherapy
bDMARD prescription in the TCZ group confirmed by our
study reflects the available evidence supporting the compara-
ble efficacy of TCZ when prescribed with or without concom-
itant MTX [6, 7, 32, 33]. However, a critical look at this
approach was risen by Gabay et al. [34] recently reporting that
despite comparable clinical response, TCZ retention was
shorter when prescribed as monotherapy. The Italian real-life
switching strategy also suggests that swapping, compared to
cycling of bDMARDs, often represents the preferred ap-
proach after failing a first-line bDMARD. ABAwas associat-
ed with a significant relative risk (RR) of 3.2 times (95% CI
1.71–6.02) of being chosen as second-line treatment com-
pared to TNFi, while TCZ showed a RRR of 2.01 (95% CI
1.2–3.36) vs TNFi. This practice has been previously demon-
strated to lead to longer drug survival, irrespective of the rea-
son for discontinuing the first TNFi [35]. In our study, second-
line TCZ was also associated with higher disease activity
compared to patients treated with TNFi. Lee et al. [36] recent-
ly analyzed the comparative efficacy and safety of different
therapeutic strategies available for RA patients not adequately
responding to TNFi and demonstrated that TCZ was the
second-line non-TNF bDMARD with the highest perfor-
mance regarding an early good response and acceptable safety
profile.
Our study has some limitations. The retrospective nature of
the analysis may be prone to assignment for treatment and
patient selection bias. Given the registry nature of the data
collection, some detailed information might be missing and
comorbidity classification (i.e., osteoporosis or autoimmune
thyroid disease, other comorbidities) may have not been fully
useful for the purposes of our study of identifying the comor-
bidities potentially influencing the treatment strategy.
Nevertheless, these information added a valuable picture on
the general prevalence of comorbidities in a large cohort of
patients treated with biological agents. Another pitfall of our
study is the relatively high percentage of missing data on
ACPA and/or RF positivity that could not therefore be used
to accurately analyze their potential role in the biologic drug
choice. Moreover, we decided not to include Rituximab in the
comparison given the relatively smaller size of the population
treated with this agent, the peculiar and well-known potential
drivers of choice associated with this agent, and the different
frequency of administration and maintenance regimen com-
pared to other bDMARDs. We could not evaluate the influ-
ence of costs or the patient’s preferences for a specific route of
administration in guiding the therapeutic decisions, as this
aspect could not be gathered from the design of the registry.
Conclusions
In conclusion, despite lack of shared consensus and clear in-
dications by international recommendations on the most ade-
quate prescribing approach of bDMARD in patients with RA,
our real-life study demonstrated that age, infectious risk, the
number and type of comorbidities, and monotherapy are the
main factors influencing the choice of the biologic drug in real
life, driving the choice towards ABA or TCZ compared to
TNFi. The interruption of previous bDMARDs due to AE
influenced the choice towards ABA. After failing a first-line
TNFi, a strategy of swapping to a different MoA is usually
more common.
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